Updated Patient Resource for Melanoma Now Available on NCCN.org/patients
The NCCN Guidelines for Patients®: Melanoma, Version 1.2014, is now available on NCCN.org/patients. This NCCN Guidelines for Patients® is a high-quality resource for patients and caregivers in the process of planning or receiving treatment. It includes the most recent test and treatment recommendations for each stage of Melanoma.
The National Comprehensive Cancer Network® (NCCN®) aims to provide people with cancer and the general public with state-of-the-art cancer treatment information in easy-to-understand language. The NCCN Guidelines for Patients, translations of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), are meant to help patients with cancer talk to their doctors about the best treatment options for the type of cancer they have.
The NCCN Guidelines for Patients®: Melanoma was developed according to plain language principles to improve health literacy. The design and format feature patient-friendly elements such as medical illustrations alongside descriptions of body parts, tests, and treatments. It also includes an expansive glossary with definitions of medical terms and acronyms.
This update includes important changes to the recommended systemic therapy options for advanced and metastatic melanoma. Two new targeted therapy drugs—dabrafenib and trametinib—and one chemotherapy drug—nab-paclitaxel—have been added as systemic therapy options. Changes were also made to the recommended frequency of follow-up tests.
NCCN currently offers NCCN Guidelines for Patients for the following: Breast, Colon, Esophageal, Non-Small Cell Lung, Ovarian, Pancreatic, and Prostate Cancers, Chronic Myelogenous Leukemia, Lung Cancer Screening, Malignant Pleural Mesothelioma, Melanoma, Multiple Myeloma, and Caring for Adolescents and Young Adults (AYA).
Funding for the NCCN Guidelines for Patients is made possible through the NCCN Foundation®.